Antisense Oligonucleotide SOD1 Inhibition for ALS Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for amyotrophic lateral sclerosis (ALS) associated with mutations in the SOD1 gene are inadequate, lacking effective options to inhibit the expression of superoxide dismutase 1 (SOD1) enzyme, which contributes to the disease's progression.
Innovation Solution
Administration of antisense oligonucleotides with specific nucleobase sequences, modified with 2′-O-methoxyethylribose and phosphorothioate linkages, via intrathecal delivery to reduce SOD1 expression, targeting the SOD1 gene mutations in ALS patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for ALS are used, then patients receive standard care, but effective inhibition of SOD1 expression is not achieved
Solution Approach 1:
The patent uses antisense oligonucleotides as intermediary molecules that bind to SOD1 mRNA to prevent protein synthesis. These oligonucleotides act as mediators between the therapeutic goal (inhibiting SOD1) and the molecular target (mRNA), enabling specific gene expression inhibition without directly interacting with the SOD1 protein itself.
Solution Approach 2:
The patent replaces traditional mechanical or chemical inhibition approaches with a molecular biology-based mechanism. Instead of using small molecules or antibodies that physically block SOD1 activity, the invention uses antisense oligonucleotides to trigger RNA interference and degrade target mRNA, substituting a biochemical mechanism for conventional therapeutic approaches.
2Reliability
If antisense oligonucleotides are administered to reduce SOD1 expression, then disease progression is slowed, but specific dosage and delivery methods are required to achieve efficacy
Solution Approach 1:
The patent employs preliminary action by administering loading doses of antisense oligonucleotides before maintenance doses. This initial high-dose phase establishes therapeutic levels of the drug in the system, ensuring effective SOD1 mRNA inhibition is achieved before transitioning to lower maintenance dosing, thereby optimizing treatment efficacy while managing complexity.
Solution Approach 2:
The patent implements periodic action through scheduled maintenance dosing intervals (e.g., every 4 weeks) after the loading phase. This periodic administration maintains therapeutic oligonucleotide levels in the cerebrospinal fluid and continues to inhibit SOD1 expression, providing sustained disease control through regular, predictable dosing cycles.
3Stability of the object's composition
If modified nucleosides and linkages are used in antisense oligonucleotides, then stability and efficacy are improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies local quality by modifying only specific positions in the oligonucleotide sequence rather than the entire molecule. The sequence contains a central region of unmodified nucleotides flanked by regions of modified nucleotides (2'-O-methoxyethyl and phosphorothioate linkages). This localized modification strategy provides enhanced stability and nuclease resistance at critical positions while simplifying synthesis compared to fully modified oligonucleotides.
Solution Approach 2:
The patent uses composite materials by combining different types of nucleoside modifications within a single oligonucleotide molecule. The structure integrates 2'-O-methoxyethyl modified nucleosides at terminal positions with phosphorothioate linkages at specific internucleoside positions, creating a composite molecule that leverages the stabilizing effects of each modification type while managing manufacturing complexity through strategic placement.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The described dosage regimens effectively reduce SOD1 protein synthesis and mRNA levels, slowing disease progression and improving motor function and respiratory outcomes in ALS patients with SOD1 mutations, as demonstrated by clinical trials.
Implementation Method 1
antisense oligonucleotides that reduce expression of superoxide dismutase 1 (SOD1)
Implementation Method 2
wherein each of nucleosides 1-5 and 16-20 are 2′-O-methoxyethylribose modified nucleosides, and each of nucleosides 6-15 are 2′-deoxynucleosides, wherein the internucleoside linkages between nucleosides 2 to 3, 4 to 5, 16 to 17, and 18 to 19 are phosphodiester linkages and the internucleoside linkages between nucleosides 1 to 2, 3 to 4, 5 to 6, 6 to 7, 7 to 8, 8 to 9, 9 to 10, 10 to 11, 11 to 12, 12 to 13, 13 to 14, 14 to 15, 15 to 16, 17 to 18, and 19 to 20 are phosphorothioate linkages
Data Source
AI summary
Dosage regimens for SOD1-targeting antisense oligonucleotides, and salts thereof, are provided. These dosage regimens find use in the treatment of subjects having or at risk of developing amyotrophic lateral sclerosis.